GlassScriptPhysician profile
Robert Carl Doekel
NPI 1023082450
$6,466.31
in general payments reported to CMS, 2019-2025
23 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $651 · 2021: $798 · 2022: $962 · 2023: $1,446 · 2024: $1,045 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,402 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.22 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,171.51 | 2019-2025 | |
| Harmony Biosciences LLC | $1,741.20 | 2020-2025 | Wakix |
| Axsome Therapeutics, INC. | $890.72 | 2023-2025 | Sunosi |
| Inspire Medical Systems, INC. | $612.76 | 2019-2023 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $505.47 | 2023-2025 | Lumryz |
| Ucb, INC. | $140.83 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $102.31 | 2019-2020 | |
| Tris Pharma INC | $45.37 | 2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $35.99 | 2023-2024 | Adzenys Xr-Odt |
| Fisher & Paykel Healthcare INC | $35.79 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.37 | 2022 | |
| Eisai INC. | $28.08 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.15 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.49 | 2024 | Horizant |
| Acella Pharmaceuticals, LLC | $19.66 | 2023 | NP Thyroid 60 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $18.84 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.52 | 2019 | |
| Resmed Corp | $14.48 | 2024 | |
| Merck Sharp & Dohme LLC | $12.77 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Doekel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.